These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 314806)

  • 1. The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB X NZW) mice. I. Long-term treatment with azathioprine and ifosfamide.
    Mitrou PS; Fischer M; Mitrou G; Röttger P; Holtz G
    Arzneimittelforschung; 1979; 29(3):483-8. PubMed ID: 314806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.
    Mitrou PS; Fischer M; Mitrou G; Röttger P
    Arzneimittelforschung; 1979; 29(4):662-7. PubMed ID: 582763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Carcinogenesis caused by immunosuppression. Tumor development in successful treatment of LE glomerulonephritis of (NBZ x NZW) mice with cytostatic agents, prednisolone and a combination of both].
    Mitrou PS; Fischer M; Mitrou G
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():862-4. PubMed ID: 612065
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice.
    Hahn BH; Knotts L; Ng M; Hamilton TR
    Arthritis Rheum; 1975; 18(2):145-52. PubMed ID: 1131283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceleration of glomerulonephritis in NZB x NZW mice by early immunization with DNA and injection of bacterial lipopolysaccharide. Experimental approach to the treatment of lupus nephritis by use of the accelerated model of NZB x NZW mouse disease.
    Fournie GJ; Minh MG; Mignon-Conte MA; Hass S; Lambert PH; Conte JJ
    J Clin Lab Immunol; 1980 Sep; 4(2):103-6. PubMed ID: 7441709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of neoplasms in female NZB/NZW mice treated with pulse doses of cyclophosphamide.
    Walker SE; Anver MR
    Vet Immunol Immunopathol; 1983 Nov; 5(1):97-104. PubMed ID: 6606891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.
    Walker SE; Anver MR
    Clin Exp Immunol; 1978 Sep; 33(3):453-62. PubMed ID: 737897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy.
    Steinberg AD; Gelfand MC; Hardin JA; Lowenthal DT
    Arthritis Rheum; 1975; 18(1):9-14. PubMed ID: 1115749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.
    Ryffel B; Car BD; Gunn H; Roman D; Hiestand P; Mihatsch MJ
    Am J Pathol; 1994 May; 144(5):927-37. PubMed ID: 8178944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of ifosfamide toxicity using dose fractionation.
    Rodriguez V; Bodey GP; Freireich EJ; McCredie KB; McKelvey EM; Tashima CK
    Cancer Res; 1976 Aug; 36(8):2945-8. PubMed ID: 1277203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early appearance of abnormally migrating serum IgM in control and cyclophosphamide-treated NZB/NZW mice.
    Walker SE
    J Rheumatol; 1982; 9(2):183-8. PubMed ID: 6980279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of NZB/NZW mice with total lymphoid irradiation: long-lasting suppression of disease without generalized immune suppression.
    Kotzin BL; Arndt R; Okada S; Ward R; Thach AB; Strober S
    J Immunol; 1986 May; 136(9):3259-65. PubMed ID: 2937842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.
    Okudaira H; Terada E; Okudaira K
    Prog Clin Biol Res; 1987; 229():157-74. PubMed ID: 3601985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
    Rudofsky UH; Evans BD; Balaban SL; Mottironi VD; Gabrielsen AE
    Lab Invest; 1993 Apr; 68(4):419-26. PubMed ID: 8479150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic abnormality in NZB/NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals.
    Mihara M; Ohsugi Y; Saito K; Miyai T; Togashi M; Ono S; Murakami S; Dobashi K; Hirayama F; Hamaoka T
    J Immunol; 1988 Jul; 141(1):85-90. PubMed ID: 3259971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented incidence of neoplasia in NZB-NZW mice treated with long-term cyclophosphamide.
    Walker SE; Bole GG
    J Lab Clin Med; 1973 Oct; 82(4):619-33. PubMed ID: 4755436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.